Notably, in the current study, we revealed that CD36 peptide treatment effectively mitigated obesity-associated non-alcoholic fatty liver disease (NAFLD), as evidenced by reduced plasma ALT and AST levels, as well as decreased liver fat accumulation. This evidence concerns the gene CD36 and obesity disorder.